All News

pneumocystis,PJP

Pneumocystis Jirovecii Pneumonia Complicating Systemic Vasculitis

Jack Cush, MD

A retrospecitive analysis of 62 patients with systemic vasculitis complicated by Pneumocystis jirovecii pneumonia (PJP) showed those with microscopic polyangiitis (MPA) had a higher mortality risk, possibly due to a higher prevalence of interstitial lung disease (ILD) in MPA.

Read Article
guidelines.jpg (keep)

British Society Guidelines for Managing Behçet’s Disease

Jack Cush, MD

An exhaustive, full read guideline from the British Association of Dermatologists (BAD) and the British Society for Rheumatology (BSR) on the management and treatment of Behçet’s disease (BD) in 2024 has been published in Rheumatology.

Read Article
RheumNow Podcast square

I Can't Treat Ugly (9.20.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and a new FDA approval for EGPA, this week on the Podcast.

Read Article
urticaria

Urticarial Vasculitis Overview

Jack Cush, MD

Urticarial vasculitis is rare and the causes often go undiagnosed. A Medscape recent overview highlights key features in the diagnosis and management of this rare disorder.

Read Article
iritis-uveitis-e1333867439592.jpg

Immunomodulatory Prevention of Uveitis Relapse in Behçet's

Jack Cush, MD

The results of a randomised, open-label, head-to-head trial shows that adalimumab was superior to ciclosporin in preventing uveitis relapses in patients with severe Behçet's disease.

Read Article
GCA,Black

IV Methylprednisolone in Giant Cell Arteritis

Jack Cush, MD

A retrospective study in giant cell arteritis (GCA) patients suggests there is no added value using higher dose, intravenous methylprednisolone (IVMP) in early GCA.

Read Article
GCA,woman

Pulse Steroids with Tocilizumab in Giant Cell Arteritis

Jack Cush, MD

A pilot study assessed pulse methoprednisolone with weekly subcutaneous tocilizumab (TCZ) in patients with large vessel-GCA (LV-GCA) and showed that a sizeable minority will relapse after the TCZ is discontinued. 

Read Article
RheumNow Podcast square

Higher Cancer Rates (8.16.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com, noting his concerns about diet, cancer, ILD, death and dosing challenges.

Read Article
RheumNow Podcast square

Depends on Where You’re Looking (8.9.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow.com this week.

Read Article
Urticarial Vasculitis Overview Urticarial vasculitis is rare and the causes often go undiagnosed. A Medscape recent overview highlights key features in the diagnosis and management of this rare disorder. https://t.co/TUlCw76asZ https://t.co/HwDQpsAtws

Links:

Dr. John Cush RheumNow ( View Tweet)
Immunomodulatory Prevention of Uveitis Relapse in Behçet's The results of a randomised, open-label, head-to-head trial shows that adalimumab was superior to ciclosporin in preventing uveitis relapses in patients with severe Behçet's disease. https://t.co/12fpuIZFmA https://t.co/iDJJq29JMA

Links:

Dr. John Cush RheumNow ( View Tweet)
ANCA-associated vasculitis analysis of 6 European registries, 3868 pts (2434 GPA, 1434 MPA), age ~57 yrs. Identified 5 clusters: 3 w/ renal dz a) variable ANCA, Hi CRP & Cr; b) MPO+; c) PR3+ & 2 extrarenal 1) PR3+ multisystem; 2) ENT w/ low CRP. Clusters better predicted outcomes… https://t.co/XZcSZ6lGjH https://t.co/yEg64YGTrA
Dr. John Cush RheumNow ( View Tweet)
IV Methylprednisolone in Giant Cell Arteritis A retrospective study in giant cell arteritis (GCA) patients suggests there is no added value using higher dose, intravenous methylprednisolone (IVMP) in early GCA. https://t.co/5udYabU5z5 https://t.co/5FHhBnAX2j

Links:

Dr. John Cush RheumNow ( View Tweet)
ANCA-associated vasculitis analysis of 6 European registries, 3868 pts (2434 GPA, 1434 MPA), age ~57 yrs. Identified 5 clusters: 3 w/ renal dz a) variable ANCA, Hi CRP & Cr; b) MPO+; c) PR3+ & 2 extrarenal 1) PR3+ multisystem; 2) ENT w/ low CRP. Clusters better predicted outcomes… https://t.co/20O58AAYAa https://t.co/KF6PTVfcRw
Dr. John Cush RheumNow ( View Tweet)
Retrospective study of 919 RTX-treated GPA pts shows TMP-SMX prophylaxis (given to 31%) assoc w/ reduced serious infections (adj HR 0.5) and less outpatient infections (aHR 0.8). All 13 pneumocystis infx (PJP) occured in those not Rx w/ TMP-SMX. https://t.co/bO6oAHv7Lr https://t.co/fPntW75hnY

Links:

Dr. John Cush RheumNow ( View Tweet)
Pulse Steroids with Tocilizumab in Giant Cell Arteritis A pilot study assessed pulse methoprednisolone with weekly subcutaneous TCZ in patients with large vessel-GCA (LV-GCA) and showed that a sizeable minority will relapse after the TCZ is discontinued. https://t.co/gGrSY3U1t9 https://t.co/zuspadaY9t

Links:

Dr. John Cush RheumNow ( View Tweet)
IgG4-related disease Nearly any organ can be affected ▶️Salivary glands ▶️Lacrimal glands ▶️Orbit ▶️Pancreatobiliary system ▶️Lung ▶️Kidney ▶️Retroperitoneum 👉🏽https://t.co/758F5iuYwT via @RheumJnl https://t.co/ipONrygHmc

Links:

Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
New! 📣Best Practice Guidelines for the management of Haemophagocytic Lymphohistiocytosis (HLH) aka Macrophage Activation Syndrome (MAS) from @NHSGIRFT @RheumatologyUK Remember the 3Fs Fever, Falling Counts, Ferritin and follow the HLH pathway to guide management… https://t.co/8oDyUbsm9W https://t.co/S0MDi3TkNk

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
Relapses with RTX Maintenance in ANCA-associated Vasculitis A real-world study on ΜPA and GPA patients found that RTX maintenance had a 25% relapse risk, with lower rates when combined with cyclophosphamide treatment. https://t.co/bD6u5JWVqS https://t.co/CSotJt4in1

Links:

Dr. John Cush RheumNow ( View Tweet)
Prospective Vasculitis Study of Takayasu’s Arteritis - 236 pts, 92% women, mean age 36 yrs, Dz duration 2.6yrs. Damage present in >80% at baseline (75% vascular, 40+% cardiac), even with recent Dx and >40% pts accrue new, mainly disease-specific damage https://t.co/DKZQdH4HuZ https://t.co/LVjqAZYnOZ

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×